Rhodanine derivatives as selective protease inhibitors against bacterial toxins.
In this study, we analyzed a series of rhodanine derivatives, as potential inhibitors of bacterial toxins, namely the proteases anthrax lethal factor and the botulinum neurotoxin type A. Conducting an extensive structure-activity relationship study on rhodanine derivatives, we profiled their selectivity against the two bacterial toxins and two related human metalloproteases using in vitro assays. In addition, we examined initial in vitro ADME-Tox properties of selected compounds and their ability to protect lethal factor-induced cell death of macrophages. These data allowed the selection of one additional drug candidate for which preliminary in vivo efficacy studies against anthrax spores were conducted. Integration of these results with our structure-activity relationship studies provides a framework for the development of potential drug candidates against anthrax and botulinum.
Johnson
Sherida L
SL
Infectious and Inflammatory Disease Center and Cancer Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Rd, La Jolla, CA 92037, USA.
Chen
Li-Hsing
LH
Harbach
Rebecca
R
Sabet
Mojgan
M
Savinov
Alexei
A
Cotton
Naomi J H
NJ
Strongin
Alex
A
Guiney
Donald
D
Pellecchia
Maurizio
M
D000942:Antigens, Bacterial; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors*; D019274:Botulinum Toxins, Type A / Q000037:antagonists & inhibitors; D006801:Humans; D008264:Macrophages / Q000187:drug effects; D045726:Metalloproteases / Q000187:drug effects; D011480:Protease Inhibitors / Q000737:chemistry*; D012236:Rhodanine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D011480:Protease Inhibitors; C030325:anthrax toxin; D012236:Rhodanine; D045726:Metalloproteases; D019274:Botulinum Toxins, Type A